Ionis Pharmaceuticals stock hits 52-week high at 49.3 USD

Ionis Pharmaceuticals Inc stock reached a 52-week high of $49.3, showing impressive momentum with a 28.5% gain over the past six months and a 22% rise year-to-date, despite experiencing a 1-year decline of -9.87%. According to InvestingPro analysis, the $6.8B market cap company is currently trading above its Fair Value. This milestone marks a notable recovery for the company, which has faced challenges over the past year. The stock’s recent performance suggests renewed investor confidence, as it climbs to its highest point in a year. InvestingPro has identified 10+ additional key insights about Ionis Pharmaceuticals’ momentum and financial health, available in the comprehensive Pro Research Report.

In other recent news, Ionis Pharmaceuticals has reported significant advancements in its clinical trials and product approvals. The company announced positive topline results from its pivotal Phase 3 CORE and CORE2 studies of olezarsen, which showed a remarkable 72% reduction in fasting triglycerides and an 85% reduction in acute pancreatitis events for patients with severe hypertriglyceridemia. These results are unprecedented for sHTG treatment. Additionally, the FDA has approved Ionis’s hereditary angioedema (HAE) treatment, Dawnzera, marking the company’s second independent product approval. Piper Sandler responded by raising its price target for Ionis to $65, maintaining an Overweight rating. Similarly, H.C. Wainwright increased its price target to $70, citing the potential of Dawnzera to capture significant market share. Wells Fargo also raised its price target to $82, emphasizing the concentrated market for HAE treatments in the U.S. Stifel maintained its Hold rating and $43 price target following the successful olezarsen trials. These developments highlight Ionis Pharmaceuticals’ recent progress and potential in the pharmaceutical industry.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.